Cargando…
Difluoromethylornithine attenuates isoproterenol-induced cardiac hypertrophy by regulating apoptosis, autophagy and the mitochondria-associated membranes pathway
Myocardial hypertrophy is an independent risk factor of cardiovascular diseases and is closely associated with the incidence of heart failure. In the present study, we hypothesized that difluoromethylornithine (DFMO) could attenuate cardiac hypertrophy through mitochondria-associated membranes (MAM)...
Autores principales: | Zhao, Yu, Jia, Wei-Wei, Ren, San, Xiao, Wei, Li, Guang-Wei, Jin, Li, Lin, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237397/ https://www.ncbi.nlm.nih.gov/pubmed/34194548 http://dx.doi.org/10.3892/etm.2021.10302 |
Ejemplares similares
-
Carbamazepine alone and in combination with doxycycline attenuates isoproterenol-induced cardiac hypertrophy
por: Errami, Mounir, et al.
Publicado: (2010) -
Dendrobium candidum aqueous extract attenuates isoproterenol-induced cardiac hypertrophy through the ERK signalling pathway
por: Cao, Yuan-Yuan, et al.
Publicado: (2020) -
Circular RNA expression in isoproterenol hydrochloride-induced cardiac hypertrophy
por: Yang, Ming-Hui, et al.
Publicado: (2020) -
Phosphocreatine Attenuates Isoproterenol-Induced Cardiac Fibrosis and Cardiomyocyte Apoptosis
por: Dai, Hui, et al.
Publicado: (2019) -
miR-139-5p inhibits isoproterenol-induced cardiac hypertrophy by targetting c-Jun
por: Ming, Su, et al.
Publicado: (2018)